> top > docs > PMC:7102560 > spans > 8332-12349 > annotations

PMC:7102560 / 8332-12349 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T41 2729-2733 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T42 2767-2779 Body_part denotes interleukins http://purl.org/sig/ont/fma/fma86578
T43 2822-2826 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T105 62-70 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T106 81-89 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T107 81-85 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T108 200-208 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T109 200-204 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T110 277-285 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T111 277-281 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T112 356-364 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T113 365-374 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T114 416-425 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T115 578-586 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T116 806-814 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T117 806-810 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T118 1062-1070 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T119 1062-1066 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T120 1110-1118 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T121 1110-1114 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T122 1807-1815 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T123 1807-1811 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T124 1846-1854 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T125 1846-1850 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T126 1963-1971 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T127 1963-1967 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T128 2004-2012 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T129 2004-2008 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T130 2179-2187 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T131 2179-2183 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T132 2356-2364 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T133 2356-2360 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T134 2930-2949 Disease denotes immune dysfunctions http://purl.obolibrary.org/obo/MONDO_0005046
T135 2964-2972 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T136 2964-2968 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T137 2989-2997 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T138 2989-2993 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T139 3302-3310 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T140 3302-3306 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T141 3430-3438 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T142 3430-3434 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T143 3962-3970 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T144 3962-3966 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T145 3999-4007 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T70 32-33 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T71 552-553 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T72 912-917 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T73 1304-1308 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T74 2642-2643 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T75 2729-2733 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T76 2820-2826 http://purl.obolibrary.org/obo/CL_0000236 denotes B cell
T77 3021-3022 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T78 3122-3127 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T79 3134-3135 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T80 3150-3151 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T81 3355-3360 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T82 3382-3383 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T26 918-926 Chemical denotes carriers http://purl.obolibrary.org/obo/CHEBI_78059
T27 2110-2119 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T28 2129-2140 Chemical denotes Oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T29 2226-2235 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T30 2712-2719 Chemical denotes steroid http://purl.obolibrary.org/obo/CHEBI_35341
T31 2767-2779 Chemical denotes interleukins http://purl.obolibrary.org/obo/CHEBI_52998
T32 3395-3399 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T33 3590-3595 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T34 3691-3696 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T35 3719-3730 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T2 2729-2751 http://purl.obolibrary.org/obo/GO_0002456 denotes cell-mediated immunity
T3 2729-2751 http://purl.obolibrary.org/obo/GO_0002449 denotes cell-mediated immunity
T4 2767-2790 http://purl.obolibrary.org/obo/GO_0001816 denotes interleukins production
T5 2820-2840 http://purl.obolibrary.org/obo/GO_0042100 denotes B cell proliferation
T6 2822-2840 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T41 416-425 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T114 0-10 Sentence denotes Discussion
T115 11-152 Sentence denotes We confirmed that in a significantly proportion of COVID-19 patients, SARS-CoV-2 reactivation developed after discharging from hospital (9%).
T116 153-224 Sentence denotes We reported clinical data from 5 patients with SARS-CoV-2 reactivation.
T117 225-375 Sentence denotes The clinical characteristics of these patients with SARS-CoV-2 reactivation were similar to those of non-reactivated patients with COVID-19 infection.
T118 376-445 Sentence denotes None of the 5 patients developed severe pneumonia or died, as of Feb.
T119 446-455 Sentence denotes 24, 2020.
T120 456-613 Sentence denotes Notably, based on our findings in these 5 patients, there is currently evidence to suggest that a proportion of recovered COVID-19 patients could reactivate.
T121 614-791 Sentence denotes The reactivated patients included 1 asymptomatic patient and 4 symptomatic patients, which suggests the reactivation potential of asymptomatic or minimally symptomatic patients.
T122 792-989 Sentence denotes The time from SARS-CoV-2 negative to positive ranged from 4 to 17 days, suggesting that recovered patients still may be virus carriers and require additional round of viral detection and isolation.
T123 990-1086 Sentence denotes We need better data to determine risk factors and mechanisms that cause SARS-CoV-2 reactivation.
T124 1087-1246 Sentence denotes The timing of onset of SARS-CoV-2 reactivation can be variable depending upon the host factors, underlying disease and the type of immunosuppressive therapies.
T125 1247-1333 Sentence denotes In our study, the recovered patients had positive RT-PCR test results 4–17 days later.
T126 1334-1484 Sentence denotes The key risk factors for reactivation would include 3 categories: (1) host status, (2) virologic factors and (3) type and degree of immunosuppression.
T127 1485-1568 Sentence denotes Host factors may include sex, older age, type of disease needing immunosuppression.
T128 1569-1715 Sentence denotes Although we could not identify risk factors for these host factors in the current study, the potential requires further large cohort confirmation.
T129 1716-1845 Sentence denotes The virologic factors associated with increased risk of reactivation include high baseline SARS-CoV-2 load and variable genotype.
T130 1846-2069 Sentence denotes SARS-CoV-2 viral load would also linked to treatment response, disease severity and progression.8 The association of SARS-CoV-2 genotypes and viral load with SARS-CoV-2 reactivation will be an important question to address.
T131 2070-2153 Sentence denotes In our study, all the patients received antiviral therapy (Oseltamivir or Arbidol).
T132 2154-2249 Sentence denotes These cases suggest that SARS-CoV-2 reactivation may occur whatever the antiviral therapy used.
T133 2250-2380 Sentence denotes These host and virologic factors are important considerations that may further increase the likelihood of SARS-CoV-2 reactivation.
T134 2381-2555 Sentence denotes Therefore, the assessment of host as well as virologic risk factors should be important caveats to help decide whether to initiate prophylactic therapy and immunosuppression.
T135 2556-2623 Sentence denotes Immunosuppressive therapies are the commonly used causative agents.
T136 2624-2698 Sentence denotes These agents have a general mechanism that inhibits many immune functions.
T137 2699-2988 Sentence denotes For example, steroid inhibits cell-mediated immunity by suppressing interleukins production which is important for T and B cell proliferation.9 It is thus not surprising that these general immunosuppressive effects result in broad immune dysfunctions and potential SARS-CoV-2 reactivation.
T138 2989-3053 Sentence denotes SARS-CoV-2 reactivation will be a vexing and persistent problem.
T139 3054-3231 Sentence denotes Considering numerous patients infected or previously exposed to the virus, such a problem poses a major public health burden in terms of global morbidity and possibly mortality.
T140 3232-3454 Sentence denotes Currently, we did not find reliable markers in predicting the risk of SARS-CoV-2 reactivation, nor there are any validated tests to determine whether a particular drug or therapy is associated with SARS-CoV-2 reactivation.
T141 3455-3521 Sentence denotes The latter point was often determined by our empirical experience.
T142 3522-3731 Sentence denotes Although decades of the experiences helped us to identify important drugs and to manage these situations appropriately, we could not accurately evaluate the risk of the drugs prior to its clinical application.
T143 3732-4017 Sentence denotes Considering the significance of this ongoing global public health emergency, although our conclusions are limited by the small sample size, we believe that the findings are important to understand the clinical characteristics and SARS-CoV-2 reactivation potential in COVID-19 patients.

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
290 71-79 Species denotes patients Tax:9606
291 81-91 Species denotes SARS-CoV-2 Tax:2697049
292 186-194 Species denotes patients Tax:9606
293 200-210 Species denotes SARS-CoV-2 Tax:2697049
294 263-271 Species denotes patients Tax:9606
295 277-287 Species denotes SARS-CoV-2 Tax:2697049
296 342-350 Species denotes patients Tax:9606
297 390-398 Species denotes patients Tax:9606
298 498-506 Species denotes patients Tax:9606
299 587-595 Species denotes patients Tax:9606
300 62-70 Disease denotes COVID-19 MESH:C000657245
301 356-364 Disease denotes COVID-19 MESH:C000657245
302 365-374 Disease denotes infection MESH:D007239
303 416-425 Disease denotes pneumonia MESH:D011014
304 429-433 Disease denotes died MESH:D003643
305 578-586 Disease denotes COVID-19 MESH:C000657245
312 630-638 Species denotes patients Tax:9606
313 663-670 Species denotes patient Tax:9606
314 689-697 Species denotes patients Tax:9606
315 782-790 Species denotes patients Tax:9606
316 806-816 Species denotes SARS-CoV-2 Tax:2697049
317 890-898 Species denotes patients Tax:9606
332 1062-1072 Species denotes SARS-CoV-2 Tax:2697049
333 1110-1120 Species denotes SARS-CoV-2 Tax:2697049
334 1275-1283 Species denotes patients Tax:9606
335 1807-1817 Species denotes SARS-CoV-2 Tax:2697049
336 1846-1856 Species denotes SARS-CoV-2 Tax:2697049
337 1963-1973 Species denotes SARS-CoV-2 Tax:2697049
338 2004-2014 Species denotes SARS-CoV-2 Tax:2697049
339 2179-2189 Species denotes SARS-CoV-2 Tax:2697049
340 2356-2366 Species denotes SARS-CoV-2 Tax:2697049
341 2964-2974 Species denotes SARS-CoV-2 Tax:2697049
342 2092-2100 Species denotes patients Tax:9606
343 2129-2140 Chemical denotes Oseltamivir MESH:D053139
344 2144-2151 Chemical denotes Arbidol MESH:C086979
345 2712-2719 Chemical denotes steroid MESH:D013256
352 2989-2999 Species denotes SARS-CoV-2 Tax:2697049
353 3075-3083 Species denotes patients Tax:9606
354 3302-3312 Species denotes SARS-CoV-2 Tax:2697049
355 3430-3440 Species denotes SARS-CoV-2 Tax:2697049
356 3084-3092 Disease denotes infected MESH:D007239
357 3221-3230 Disease denotes mortality MESH:D003643
361 3962-3972 Species denotes SARS-CoV-2 Tax:2697049
362 4008-4016 Species denotes patients Tax:9606
363 3999-4007 Disease denotes COVID-19 MESH:C000657245

2_test

Id Subject Object Predicate Lexical cue
32171867-17293163-61116998 2841-2842 17293163 denotes 9